SU519138A3 - Способ выращивани вируса щура - Google Patents
Способ выращивани вируса щураInfo
- Publication number
- SU519138A3 SU519138A3 SU1882920A SU1882920A SU519138A3 SU 519138 A3 SU519138 A3 SU 519138A3 SU 1882920 A SU1882920 A SU 1882920A SU 1882920 A SU1882920 A SU 1882920A SU 519138 A3 SU519138 A3 SU 519138A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- virus
- suspension
- cultivation
- hours
- growing
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 31
- 238000000034 method Methods 0.000 title description 5
- 239000000725 suspension Substances 0.000 claims description 15
- 241000283690 Bos taurus Species 0.000 claims description 5
- 210000002919 epithelial cell Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 3
- 241000282849 Ruminantia Species 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004767 rumen Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000190534 Inkoo virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000220221 Rosales Species 0.000 description 1
- 101710140501 Sulfate adenylyltransferase subunit 2 1 Proteins 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- ALNUHUMOGUVHIO-XXJNWDAFSA-M sodium;7-[(1r,2s)-2-hexyl-5-hydroxycyclopentyl]heptanoate Chemical compound [Na+].CCCCCC[C@H]1CCC(O)[C@@H]1CCCCCCC([O-])=O ALNUHUMOGUVHIO-XXJNWDAFSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940031418 trivalent vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/135—Foot- and mouth-disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
- C12N2770/32161—Methods of inactivation or attenuation
- C12N2770/32164—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2206779A DE2206779A1 (de) | 1972-02-12 | 1972-02-12 | Verfahren zur massenzuechtung von mksviren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU519138A3 true SU519138A3 (ru) | 1976-06-25 |
Family
ID=5835863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU1882920A SU519138A3 (ru) | 1972-02-12 | 1973-01-31 | Способ выращивани вируса щура |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS4891262A (enExample) |
| AR (1) | AR193480A1 (enExample) |
| AT (1) | AT321464B (enExample) |
| BE (1) | BE795293A (enExample) |
| CH (1) | CH577031A5 (enExample) |
| CS (1) | CS199547B2 (enExample) |
| DD (1) | DD105252A5 (enExample) |
| DE (1) | DE2206779A1 (enExample) |
| DK (1) | DK137766C (enExample) |
| ES (1) | ES411484A1 (enExample) |
| FR (1) | FR2171425B1 (enExample) |
| GB (1) | GB1375154A (enExample) |
| KE (1) | KE2550A (enExample) |
| NL (1) | NL7301892A (enExample) |
| RO (1) | RO62814A (enExample) |
| SU (1) | SU519138A3 (enExample) |
| ZA (1) | ZA73926B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109097320A (zh) * | 2018-07-23 | 2018-12-28 | 南京农业大学 | 一种绵羊羔羊瘤胃上皮细胞培养方法 |
-
0
- BE BE795293D patent/BE795293A/xx unknown
-
1972
- 1972-02-12 DE DE2206779A patent/DE2206779A1/de active Pending
-
1973
- 1973-01-31 SU SU1882920A patent/SU519138A3/ru active
- 1973-02-03 AR AR246515A patent/AR193480A1/es active
- 1973-02-09 RO RO197373792A patent/RO62814A/ro unknown
- 1973-02-09 CH CH186773A patent/CH577031A5/xx not_active IP Right Cessation
- 1973-02-09 AT AT121073A patent/AT321464B/de not_active IP Right Cessation
- 1973-02-09 ZA ZA730926A patent/ZA73926B/xx unknown
- 1973-02-09 DD DD168792A patent/DD105252A5/xx unknown
- 1973-02-09 DK DK73173A patent/DK137766C/da active
- 1973-02-09 JP JP48015801A patent/JPS4891262A/ja active Pending
- 1973-02-09 NL NL7301892A patent/NL7301892A/xx not_active Application Discontinuation
- 1973-02-10 ES ES411484A patent/ES411484A1/es not_active Expired
- 1973-02-12 CS CS731009A patent/CS199547B2/cs unknown
- 1973-02-12 FR FR7304836A patent/FR2171425B1/fr not_active Expired
- 1973-02-12 GB GB680173A patent/GB1375154A/en not_active Expired
-
1975
- 1975-08-08 KE KE2550*UA patent/KE2550A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS4891262A (enExample) | 1973-11-28 |
| AR193480A1 (es) | 1973-04-23 |
| DK137766C (da) | 1978-10-09 |
| FR2171425B1 (enExample) | 1976-11-05 |
| ZA73926B (en) | 1973-11-28 |
| AT321464B (de) | 1975-04-10 |
| GB1375154A (enExample) | 1974-11-27 |
| FR2171425A1 (enExample) | 1973-09-21 |
| RO62814A (fr) | 1977-11-15 |
| CH577031A5 (enExample) | 1976-06-30 |
| NL7301892A (enExample) | 1973-08-14 |
| CS199547B2 (en) | 1980-07-31 |
| DE2206779A1 (de) | 1973-08-16 |
| KE2550A (en) | 1975-08-22 |
| ES411484A1 (es) | 1976-01-01 |
| BE795293A (fr) | 1973-08-13 |
| DD105252A5 (enExample) | 1974-04-12 |
| DK137766B (da) | 1978-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fishman | Antibody formation in vitro | |
| KR840001512B1 (ko) | 백일해 톡소이드의 제조방법 | |
| CN112410239A (zh) | 细菌膜囊泡及其制备方法与应用 | |
| CN112402601A (zh) | 金黄色葡萄球菌膜囊泡及其制备方法与应用 | |
| JP3043809B2 (ja) | グラム陰性菌ワクチン | |
| SU519138A3 (ru) | Способ выращивани вируса щура | |
| CN111662870A (zh) | 卡介菌多糖核酸在cik细胞体外培养及制备肿瘤药物中的应用 | |
| CN113663056A (zh) | Tnfsf15蛋白作为淋巴细胞免疫增强剂的应用及其活化方法 | |
| US3395218A (en) | Nonliving nematode vaccines | |
| Eaton et al. | Studies on sensitivity to streptomycin of the atypical pneumonia agent | |
| Wesslén et al. | The inactivation of foot-and-mouth disease virus by formalin | |
| KR940004541B1 (ko) | 트레포네마 히오디센테리아 박테린의 제조방법 | |
| AU2020103625A4 (en) | Applications of bacillus calmette-guerin (bcg) polysaccharide and nucleic acid in in-vitro culture of cytokine-induced-killer (cik) cells and preparation of antitumor drugs | |
| US2867567A (en) | Process of preparing anti-haemophilic globulin | |
| JPS58183627A (ja) | 免疫生物学的調製物 | |
| SU997599A3 (ru) | Способ получени гетеровакцины дл лечени синдрома трихомонада | |
| US2720485A (en) | Preparation of concentrated, purified ultraviolet inactivated hog cholera vaccine | |
| Ezell et al. | Soluble specific leptospiral complement-fixing antigens | |
| US3318775A (en) | Production of viral antigens with n-acetyl-ethyleneimine | |
| US3660565A (en) | Rubella vaccine and method | |
| CA1243949A (en) | Processes for development of acceptance of transplanted organs and tissues | |
| RU2255766C2 (ru) | Способ получения иммуноглобулинового препарата для профилактики и терапии бактериальных и вирусных инфекций, иммуноглобулиновый препарат для профилактики и терапии бактериальных и вирусных инфекций (варианты) и суппозитории на основе иммуноглобулинового препарата | |
| RU2070819C1 (ru) | Способ получения вакцины против эшерихиоза телят | |
| Ruiz-Castaneda | Active immunization against epidemic typhus by means of vaccines prepared from endemic virus | |
| CN114940976B (zh) | 一种过表达融合蛋白ptgfrn-glp-1工程化外泌体的制备方法及其应用 |